

CONTACT: Robert Murphy
Jitsu Public Relations, Inc.
(908) 276-0777
rmurphy@jitsuPR.com

FOR IMMEDIATE RELEASE

TERUMO INTERVENTIONAL SYSTEMS ENTERS THE LARGE BORE ACCESS SHEATH MARKET WITH U.S. LAUNCH OF SOLOPATH® BALLOON EXPANDABLE TRANSFEMORAL ACCESS SYSTEM

Revolutionary Sheath Technology Combines Smallest Insertion Profiles with Largest Internal Diameters Available, Providing Unprecedented Vessel Access and Expandability When Delivery of Large Devices is Critical

SOMERSET, NJ (October 22, 2012) – Terumo Interventional Systems, a strategic business unit of Terumo Medical Corporation, a leading manufacturer of guidewires, catheters, sheaths, and embolization products, and a proven leader in vascular access solutions, today announced the nationwide launch of the revolutionary SoloPath® Balloon Expandable Transfemoral Access System, designed to be inserted percutaneously in the femoral artery and provide a guide for various catheters and devices. The large inner diameter of the sheath allows for access during procedures that involve devices such as percutaneous valve implants, endovascular grafts and valvuloplasty balloons.

The SoloPath access system, featuring Onset Medical Corporation's ("Onset") proprietary Controlled Deployment Technology (CDT) platform, provides the smallest sheath insertion profiles of any available access sheath, while still providing the large internal diameters physicians require. The device's low profile, malleable design, large internal diameter, and hydrophilic coating may help facilitate delivery in difficult anatomy, minimize insertion forces, and may reduce access site or arterial trauma associated with sheath insertion.

"The SoloPath access system's remarkably small insertion profile, unmatched malleability, and collapsibility offer significant advantages when compared to larger, more rigid conventional sheaths in the treatment of complex, large-bore interventional procedures," said Erin Moore, MD, Vascular and Endovascular Surgeon, Baptist Medical Center, Jacksonville, Florida. "SoloPath's hydrophilic coating mitigates intimal wall friction and trauma, facilitating easier insertion and removal as well as successful navigation through complex vascular anatomy."

Onset's patented, balloon-expanding technology allows SoloPath introducer sheaths to be delivered with a lower profile, enabling less-traumatic insertion into and removal from the femoral-iliac vessels. This smaller profile may reduce the potential for vascular complications experienced by conventional bore large sheaths, and may reduce the need for these types of procedures to be managed via more invasive measures.

“With the addition of SoloPath, Terumo now offers a complete product portfolio dedicated to access management in micro- to macro-interventions. The addition of the SoloPath access system with CDT technology provides a powerful tool that may change the way physicians perform endovascular procedures in complex anatomy,” said Chris Pearson, Vice President, Marketing, Terumo Interventional Systems. “Current literature supports the fact that in procedures involving access by large bore devices through the femoral artery, the most common complication is vascular access. Unlike any other large bore sheath, the SoloPath device provides innovative malleable properties and radial expansion technology, which may aid physicians in achieving a successful outcome by helping to reduce access-related events or by potentially allowing physicians to treat patients in a more minimally invasive manner. This device provides physicians a simplified, one-step transfemoral endovascular access procedure and replaces the need for conventional, rigid sheaths.”

For additional information about the SoloPath® Balloon Expandable Transfemoral Access System, visit www.terumo.com or connect to your local Terumo sales representative by calling 800-862-4143.

Terumo Interventional Systems

Terumo Interventional Systems (TIS) is a strategic business unit of Terumo Medical Corporation. As a market leader in entry site management and lesion access, TIS is committed to pursuing unique technologies designed to enhance treatment of coronary and peripheral endovascular diseases as well as driving strategic initiatives focused on Critical Limb Ischemia, Complex Coronary Intervention and Transradial Access.

TIS directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures.

Terumo Medical Corporation

Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets a complete, solutions-based portfolio of high-quality medical devices used in a broad range of applications for numerous areas of the healthcare industry. TMC is comprised of two business divisions: Terumo Interventional Systems and Terumo Medical Products. The company places a premium on providing customers with world-class products, training and education programs that drive clear economic value, better clinical outcomes and improved Quality of Life for patients.

Terumo Corporation

Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers with \$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve.

Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan’s leading stock index.